On July 29, 2026, a delegation from Yichang visited the Cell Valley Group for site inspection and exchange. The delegation included Jing Rui, Deputy Director of the Yichang Municipal Investment Promotion Bureau; Zhang Weijiang, Deputy General Manager of Yichang Industry Investment Group State-owned Investment Company; Gong Hongchao, Section Chief of the Second Investment Promotion Division of the Yichang Municipal Investment Promotion Bureau; Liu Jing, Deputy Head of the Traditional Chinese Medicine Policy Division of the Yichang Health Commission; Zhou Yuanhong, Deputy Director of the Scientific Research Department of Yichang Central People's Hospital; and Li Min, Chief Technologist of the Central Laboratory of Yichang Central People's Hospital. Professor Wang Jianxun, Chief Scientist of the Cell Valley Group; Xiang Hua, Deputy General Manager; and Wang Shaoqing, Chief Financial Officer, extended a warm welcome. The parties engaged in in-depth discussions on topics including the construction model for regional cell industry public service platforms, pathways for clinical research collaboration with top-tier tertiary hospitals, guarantees for industrial implementation elements, project investment cooperation models, and compliant clinical translation pathways for emerging biomedical technologies.

The delegation toured the Group's multi-functional exhibition hall, standardized GMP production workshop, and R&D laboratories, gaining hands-on understanding of the Group's platform development history, full-industry-chain strategic layout, core technology systems, and practical achievements in clinical translation of emerging biomedical technologies. Through on-site explanations and case presentations, the delegation gained an intuitive appreciation of Cell Valley's accumulated practical experience in CGT process development, quality control, and hospital-enterprise project implementation, as well as a comprehensive understanding of the complete pathway from cell therapy technology R&D to clinical application. The delegation acknowledged and affirmed the Group's industrialization achievements.

During the symposium, Deputy General Manager Xiang Hua extended a warm welcome to the Yichang government-enterprise-medical delegation and introduced the Group's overall business layout, providing an in-depth interpretation of the integrated "technology platform + clinical translation + regional implementation" operation model and sharing practical experience in operating cell public industry platforms across multiple regions. He noted that Cell Valley has been deeply engaged in full-chain services for cell and gene therapy, possessing comprehensive technology platforms, project operations, and industrial implementation expertise. He expressed strong optimism for Yichang's high-quality medical resources, industrial foundation, and business environment, and looked forward to fully leveraging the company's technological and platform advantages to connect with local medical institutions and state-owned platform resources in Yichang, exploring feasible hospital-enterprise collaboration models, helping cutting-edge medical technologies serve local clinical needs, and empowering the upgrading and quality improvement of the local biomedical industry.

Deputy Director Jing Rui highly recognized the achievements of Cell Valley in the cell industry and introduced the current state of Yichang's biomedical industry development, the resource advantages of the Central Hospital, local industrial support policies, and investment strategic directions. Yichang is actively fostering life and health as a strategic emerging industry. He expressed hope to leverage local hospital clinical resources and state-owned industrial investment platforms to break down barriers among research, clinical practice, and industry, and to engage in deep cooperation with Cell Valley on research projects and industrial development, driving the deep integration of innovative technologies with local development.

This symposium further enhanced communication and mutual trust among the Yichang Municipal Investment Promotion Bureau, the Municipal Health Commission, the hospital, and the Cell Valley Group, laying a solid foundation for deepening hospital-enterprise collaboration, government-enterprise synergy, and accelerating the high-quality development of the regional life and health industry.